-
Sutent OKed as pancreatic NET treatment
NEW YORK — The Food and Drug Administration has approved a Pfizer drug for treating pancreatic tumors.
Pfizer announced Friday the approval of Sutent (sunitinib malate) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with locally advanced disease that can’t be removed through surgery. Pancreatic NET is a rare cancer reported in 2 million to 4 million people worldwide every year.
-
Amneal to manufacture generic Furadantin
BRIDGEWATER, N.J. — A generic drug maker has been granted approval from the Food and Drug Administration to manufacture its version of a urinary tract infection treatment.
Amneal Pharmaceuticals said that its nitrofurantoin oral suspension in the 25-mg/5-mL strength is the first-to-market, AB-rated, generic version of Furadantin, which is made by Shionogi Pharma.
Amneal will sell its generic in 8-oz./230-mL size bottles, the company said.